AW
ALXN

ACG Wealth’s Alexion Pharmaceuticals ALXN Stock Holding History

ACG Wealth’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-100
Closed -$16K – 351
2020
Q4 		$16K Hold
100
– – ﹤0.01% 310
2020
Q3 		$11K Buy
+100
New +$10.8K ﹤0.01% 290

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

ACG Wealth's ALXN Position: Q3 2021 in Review

ACG Wealth sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 13,498 shares — an estimated $2.48M sold.

ACG Wealth first reported a position in ALXN in Q1 2020 and held it in 6 quarters. The position peaked at $5.34M in Q4 2020. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • ACG Wealth reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • ACG Wealth sold 13,498 Alexion Pharmaceuticals shares in Q3 2021, an estimated $2.48M.
  • ACG Wealth first reported a position in Alexion Pharmaceuticals in Q1 2020 and held it in 6 quarters.
  • ACG Wealth's Alexion Pharmaceuticals position peaked at $5.34M in Q4 2020.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on ACG Wealth's 13F filing for Q3 2021, filed 1 Nov 2021.